Physician profile
Tyler Bates
NPI 1508575374
$810.43
in general payments reported to CMS, 2019-2025
18 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $182 · 2024: $214 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $121.74 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $100.31 | 2023-2025 | Farxiga, Airsupra |
| Astellas Pharma US INC | $90.96 | 2025 | Veozah |
| Pfizer INC. | $78.21 | 2023-2025 | |
| Abbott Laboratories | $57.99 | 2025 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $47.44 | 2024 | Inspire |
| Organon LLC | $44.01 | 2023-2024 | Nexplanon |
| Abbvie INC. | $33.55 | 2024-2025 | |
| Axsome Therapeutics, INC. | $30.17 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $29.65 | 2024-2025 | Vaxelis, Gardasil 9, Capvaxive |
| Novartis Pharmaceuticals Corporation | $27.89 | 2024 | |
| Glaxosmithkline, LLC. | $26.16 | 2023 | Arexvy, Trelegy Ellipta |
| Lundbeck LLC | $25.65 | 2025 | Rexulti |
| Lucid Diagnostics INC. | $24.21 | 2023 | |
| Exact Sciences Corporation | $23.80 | 2023 | Cologuard Collection Kit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $18.41 | 2025 | Zepbound, Mounjaro |
| Idorsia Pharmaceuticals US INC | $16.21 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $14.07 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.